Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Journal of Enzyme Inhibition and Medicinal Chemistry
|
August 18, 2025
High-throughput virtual screening, identification and <i>in vitro</i> biological evaluation of novel inhibitors of PLK1 and NRP1
Yang Xia, Yuting Chang, Lixia Guan, et al.
Medicine
|
March 12, 2019
Increased expression of plakophilin 3 is associated with poor prognosis in ovarian cancer
Hua Qian, Donglan Yuan, Jingjing Bao, et al.
Small (Weinheim an Der Bergstrasse, Germany)
|
November 11, 2020
Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and miRNAs
Sisi Zhou, Tao Hu, Gaohua Han, et al.
ACS Nano
|
November 21, 2023
A Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-Immunotherapy
Wenhao Shen, Pei Pei, Chonghai Zhang, et al.
Frontiers in Immunology
|
November 29, 2023
Association of genes in hereditary metabolic diseases with diagnosis, prognosis, and treatment outcomes in gastric cancer
Yiping Li, Xiaoqin Li, Yufei Yang, et al.
International Journal of Cancer
|
August 8, 2025
Comparisons of blood, upper respiratory tract and gut viromes from patients with lung cancer and healthy persons
Wang Li, Shaokun Pan, Jin Qian, et al.
Frontiers in Immunology
|
November 29, 2023
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)
Yizhang Chen, Jiaguang Zhang, Gaohua Han, et al.
Signal Transduction and Targeted Therapy
|
December 1, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib
Yuankai Shi, Dongqing Lv, Weineng Feng, et al.
Cell Death and Differentiation
|
October 31, 2025
CRISPR/Cas9 library screening uncovered CCT2 as a critical driver of acquired resistance to EGFR-targeted therapy by stabilizing TMX1 in non-small cell lung cancer
Zihao Ke, Qi Zhang, Xingyu Chen, et al.
Journal for Immunotherapy of Cancer
|
November 11, 2020
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
Xiaofeng Chen, Xiaofeng Wu, Hao Wu, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Journal of Enzyme Inhibition and Medicinal Chemistry
|
August 18, 2025
High-throughput virtual screening, identification and <i>in vitro</i> biological evaluation of novel inhibitors of PLK1 and NRP1
Yang Xia, Yuting Chang, Lixia Guan, et al.
Medicine
|
March 12, 2019
Increased expression of plakophilin 3 is associated with poor prognosis in ovarian cancer
Hua Qian, Donglan Yuan, Jingjing Bao, et al.
Small (Weinheim an Der Bergstrasse, Germany)
|
November 11, 2020
Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and miRNAs
Sisi Zhou, Tao Hu, Gaohua Han, et al.
ACS Nano
|
November 21, 2023
A Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-Immunotherapy
Wenhao Shen, Pei Pei, Chonghai Zhang, et al.
Frontiers in Immunology
|
November 29, 2023
Association of genes in hereditary metabolic diseases with diagnosis, prognosis, and treatment outcomes in gastric cancer
Yiping Li, Xiaoqin Li, Yufei Yang, et al.
International Journal of Cancer
|
August 8, 2025
Comparisons of blood, upper respiratory tract and gut viromes from patients with lung cancer and healthy persons
Wang Li, Shaokun Pan, Jin Qian, et al.
Frontiers in Immunology
|
November 29, 2023
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)
Yizhang Chen, Jiaguang Zhang, Gaohua Han, et al.
Signal Transduction and Targeted Therapy
|
December 1, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib
Yuankai Shi, Dongqing Lv, Weineng Feng, et al.
Cell Death and Differentiation
|
October 31, 2025
CRISPR/Cas9 library screening uncovered CCT2 as a critical driver of acquired resistance to EGFR-targeted therapy by stabilizing TMX1 in non-small cell lung cancer
Zihao Ke, Qi Zhang, Xingyu Chen, et al.
Journal for Immunotherapy of Cancer
|
November 11, 2020
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
Xiaofeng Chen, Xiaofeng Wu, Hao Wu, et al.
Page
of 5